• 1
    Armstrong, B. K. and A. Kricker (1994) Cutaneous melanoma. Cancer Surv. 19, 219240.
  • 2
    Albino, A. P. and J. W. Fountain (1993) The molecular genetics of malignant melanoma. In Cancer Treatment and Research: Basic and Clinical Aspects of Malignant Melanoma (Edited by L.Nathanson), pp. 201255. Martinus Nijhoff, Boston .
  • 3
    Clark, W. H., Jr, D. E. Elder, D. Guerry, M. N. Epstein, M. H. Greene and M. Van Horn (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol. 15, 11471165.
  • 4
    Hinds, P. W. and R. A. Weinberg (1994) Tumor suppressor genes. Curr. Opin. Genet. Dev. 4, 135141.
  • 5
    Baserga, R. (1994) Oncogenes and the strategy of growth factors. Cell 79, 927930.
  • 6
    Fountain, J. W., S. J. Bale, D. E. Housman and N. C. Dracopoli (1990) Genetics of melanoma. In Cancer Surveys: Advances and Prospects in Clinical, Epidemiological and Laboratory Oncology (Edited by L. M.Franks), pp. 645671. Oxford University Press, London .
  • 7
    Thompson, F. H., J. Emerson, S. Olson, R. Weinstein, S. A. Leavitt, S. P. L. Leong, S. Emerson, J. M. Trent, M. A. Nelson, S. E. Salmon and R. Taetle (1995) Cytogenetics in 158 patients with regional or disseminated melanoma. Cancer Genet. Cytogenet (In press).
  • 8
    Petty, E., L. Gibson, J. Fountain, J. Bolognia, T. Yang Feng, D. Housman and A. Bale (1993) Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). Am. J. Hum. Genet. 53, 96104.
  • 9
    Goldstein, A., N. Dracopoli, M. Engelstein, M. Fraser, W. Clark, Jr. and M. Tucker (1994) Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. Hum. Genet. 54, 489496.
  • 10
    Cannon-Albright, L., D. Goldgar, L. Meyer, C. Lewis, D. Anderson, J. Fountain, M. Hegi, R. Wiseman, E. Petty and A. Bale (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258, 11481152.
  • 11
    Greene, M. H. and J. F. Fraumeni, Jr. (1979) The hereditary variant of malignant melanoma. In Human Malignant Melanoma (Edited by W. H.Clark, L. I.Goldman and M. J.Mas-trangelo), pp. 139166. Grune & Stratton, New York .
  • 12
    Kamb, A., N. A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harsh-man, S. V. Tavtigian, E. Stockert, R. S. Day, III, B. E. Johnson and M. H. Skolnick (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436440.
  • 13
    Serrano, M., G. J. Hannon and D. Beach (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704707.
  • 14
    Merlo, A., J. G. Herman, L. Mao, D. J. Lee, E. Gabrielson, P. C. Burger, S. B. Baylin and D. Sidransky (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p 16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686692.
  • 15
    Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. DePlaen, T. Hankeln, K.-H. Meyer and D. Beach (1995) A p16INK4A-insensitive CDK4 mutant targeted by cytolytic T-lymphocytes in a human melanoma. Science 269, 12811284.
  • 16
    Lukus, J., D. Parry, L. Aagaard, D. J. Mann, J. Bartkova, M. Strauss, G. Peters and J. Bartek (1995) Retinoblastoma-protein dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503506.
  • 17
    Glendening, J. M., J. F. Flores, G. J. Walker, S. Stone, A. P. Albino and J. W. Fountain (1995) Homozygous loss of the pl5INK4B gnee (and not the pl6INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res. 55, 55315535.
  • 18
    Hannon, G. and D. Beach (1994) pl5INK4B is a potential ef Photochemistry and Photobiology, 1996, 63(4) 417 fector of TGF-beta-induced cell cycle arrest. Nature 371, 257261.
  • 19
    Walker, G. J., J. M. Palmer, M. K. Walters and N. K. Hayward (1995) A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer 12, 134141.
  • 20
    Lahti, J. M., M. Valentine, J. Xiang, B. Jones, J. Amann, J. Grenet, G. Richmond, A. T. Look and V. J. Kidd (1994) Alterations in the PITSLRE protein kinase gene complex on chromosome lp36 in childhood neuroblastoma. Nature Genet. 7, 370375.
  • 21
    Lahti, J. M., J. Xiang, L. S. Heath, D. Campana and V. J. Kidd (1995) PITSLRE protein kinase activity is associated with apoptosis. Mol. Cell. Biol. 15, 111.
  • 22
    Xiang, J., J. M. Lahti, J. Grenet, J. Easton and V. J. Kidd (1994) Molecular cloning and expression of alternatively spliced PITSLRE protein kinase isoforms. J. Biol. Chem. 269, 1578615794.
  • 23
    Walker, G. J., D. J. Nancarrow, M. K. Walters, J. M. Palmer, J. L. Weber and N. K. Hayward (1994) Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int. J. Cancer 59, 771775.
  • 24
    Koprowski, H., M. Herlyn, G. Balaban, A. Parmiter, A. Ross and P. Nowell (1985) Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat. Cell Mol. Genet. 11, 297302.
  • 25
    Wiltshire, R. N., P. Duray, M. L. Bittner, T. Visakorpi, P. S. Meltzer, R. J. Tuthill, L. A. Liotta and J. M. Trent (1995) Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res. 55, 39543957.
  • 26
    Herbst, R. A., A. Larson, J. Weiss, W. K. Cavenee, G. M. Hampton and K. C. Arden (1995) A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. Cancer Res. 55, 24942496.
  • 27
    Ozisik, Y. Y., A. M. Meloni, O. Altungoz, A. Peier, C. Karak-ousis, S. P. L. Leong and A. A. Sandbergen (1994) Cytogenetic findings in 21 malignant melanomas. Cancer Genet. Cytogenet. 77, 6973.
  • 28
    Hunter, T. and J. Pines (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79, 573582.
  • 29
    Weinert, T. and D. Lydell (1993) Cell cycle checkpoints, genetic instability and cancer. Cancer Biol. 4, 129140.
  • 30
    Rosen, C. F., Y. Sek, W. Farinell, R. S. Stern, T. B. Fitzpatrick, M. A. Pathak and R. W. Gange (1987) A comparison of the melanocyte response to narrow band UVA and UVB exposure in vivo. J. Invest. Dermatol. 88, 774779.
  • 31
    Friedberg, E. C., G. C. Walker and W. Siede (1995) DNA repair and mutagenesis ASM Press, Washington , DC .
  • 32
    McMillan, T. J. (1992) Residual DNA damage: what is left over and how does this determine cell fate. Eur. J. Cancer 28, 267269.
  • 33
    Greenblatt, M. S., W. P. Bennett, M. Hollstein and C. C. Harris (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 48554878.
  • 34
    Hall, P. A., P. H. Mckee, H. du P. Menage, R. Dover and D. P. Lane (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8, 203207.
  • 35
    Loganzo, F., Jr., Y. Nabeya, P. Maslak and A. P. Albino (1994) Stabilization of p53 protein is a critical response to UV radiation in human melanocytes: implications for melanoma development. Mol. Cell Differ. 2, 2343.
  • 36
    El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler and B. Vogelstein (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817825.
  • 37
    Albino, A. P., M. Vidal, N. S. McNutt, C. R. Shea, V. G. Prieto, D. M. Nanus, J. M. Palmer and N. K. Hayward (1994) Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 4, 3545.
  • 38
    Saenz-Santamaria, M. C., N. S. McNutt, J. K. Bogdany and C. R. Shea (1995) p53 expression is rare in cutaneous melanomas. Am. J. Dermatopathol. 17, 344349.
  • 39
    Hatton, D. H., D. L. Mitchell, P. T. Strickland and R. T. Johnson (1995) Enhanced photoproduct repair: its role in the DNA damage-resistance phenotype of human malignant melanoma cells. Cancer Res. 55, 181189.
  • 40
    Vidal, M. J., N. K. Hayward and A. P. Albino (1995) Mutations in the WAF1 tumor suppressor gene occur infrequently in sporadic and familial malignant melanomas. Melanoma Res. 5, 243250.
  • 41
    Lowe, S. W., H. E. Ruley, T. Jacks and D. E. Housman (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957967.
  • 42
    Korsmeyer, S. J. (1992) Bcl-2: an antidote to programmed cell death. Cancer Surv. 15, 105118.
  • 43
    Saenz-Santamaria, M. C., J. A. Reed, N. S. McNutt and C. R. Shea (1994) Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J. Cutan. Pathol. 21, 393397.
  • 44
    Hart, I. R., N. T. Goode and R. E. Wilson (1989) Molecular aspects of the metastatic cascade. Biochim. Biophys. Acta 989, 6584.
  • 45
    Stetler Stevenson W. G., S. Aznavoorian and L. A. Liotta (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9, 541573.
  • 46
    de Vries, T. J., P. H. Quax, M. Denijn, K. N. Verrijp, J. H. Verheijen, H. W. Verspaget, U. H. Weidle, D. J. Ruiter and G. N. Van Muijen (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocyte tumor progression. Am. J. Pathol. 144, 7081.
  • 47
    Edward, M. (1995) Integrins and other adhesion molecules involved in melanocytic tumor progression. Curr. Opin. Oncol. 7, 185191.
  • 48
    Altomonte, M., A. Gloghini, G. Bertola, A. Gasparollo, A. Car-bone, S. Ferrone and M. Maio (1993) Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 53, 33433348.
  • 49
    Alileche, A., S. Plaisance, D. S. Han, E. Rubinstein, C. Mingari, R. Bellomo, C. Jasmin and B. Azzarone (1993) Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene 8, 17911796.
  • 50
    van den Brule, F. A., C. Buicu, M. Baldet, M. E. Sobel, D. N. Cooper, P. Marschal and V. Castronovo (1995) Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem. Biophys. Res. Commun. 209, 760767.
  • 51
    Jenq, W., S. J. Wu and N. A. Kefalides (1994) Expression of the alpha-2 subunit of laminin correlates with increased cell adhesion and metastatic propensity. Differentiation 58, 2936.
  • 52
    Sers, C., G. Riethmuller and J. P. Johnson (1994) MTJC18, a melanoma-progression associated molecule and its potential role in tumor vascularization and hematogenous spread. Cancer Res. 54, 56895694.
  • 53
    Danen, E. H. J., G. N. P. van Muijen and D. J. Ruiter (1995) Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Cancer Surv. 24, 4365.
  • 54
    Seftor, R. E. B., E. A. Seftor, W. G. Stetler-Stevenson and M. J. C. Hendrix (1993) The 72 kDa type IV collagenase is modulated via differential expression of αvβ3 and α5β1 integrins during human melanoma cell invasion. Cancer Res. 53, 34113415.
  • 55
    Reed, J. A., N. S. McNutt, V. G. Prieto and A. P. Albino (1994) Expression of transforming growth factor-β2 in malignant melanoma correlates with the depth of tumor invasion: implications for tumor progression. Am. J. Pathol. 145, 97104.
  • 56
    Bodmer, S., K. Strornmer, K. Frei, C. Siepl, N. de Tribolet, I. Heid and A. Fontana (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J. Immunol. 143, 32223229.
  • 57
    Kerbel, R. S. (1992) Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am. J. Pathol. 141, 519524.
  • 58
    Lu, C. and R. S. Kerbel (1993) Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol. 120, 12811288.
  • 59
    MacDougall, J., H. Kobayashi and R. S. Kerbel (1993) Responsiveness of normal/dysplastic melanocytes and melanoma cells from different lesional stages of disease progression to the growth inhibitory effects of TGFβ. Mol. Cell Differ. 1, 2140.
  • 60
    Rodeck, U. (1993) Growth factor independence and growth regulatory pathways in human melanoma development. Cancer Metastasis Rev. 12, 219226.
  • 61
    Albino, A. P., B. M. Davis and D. M. Nanus (1991) Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res. 51, 48154820.
  • 62
    Mattei, S., M. P. Colombo, C. Melani, G. Parmiani and M. Herlyn (1994) Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int. J. Cancer 56, 853857.
  • 63
    Ciotti, P., M. L. Rainero, N. B. Spina, C. Garre, F. Casabona, P. L. Santi and G. Bianchi-Scarra (1995) Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Res. 5, 4147.
  • 64
    Singh, R. K., M. Gutman, R. Reich and M. Bar-Eli (1995) Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of in-terleukin–8. Cancer Res. 55, 36693674.
  • 65
    Scheibenbogen, C., T. Mohler, J. Haefele, W. Hunstein and U. Keiholz (1995) Serum interleukin-8 is elevated in patients with metastatic melanoma and corelate with tumor load. Melanoma Res. 5, 179181.
  • 66
    Dummer, W., J. C. Becker, A. Schwaaf, M. Leverkus, T. Moll and E. B. Brocker (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 5, 6768.
  • 67
    Yamanishi, D. T., J. A. Buckmeier and F. L. Meyskens, Jr. (1991) Expression of c-jun, jun-B, and c-fos protooncogenes in human primary melanocytes and metastatic melanomas. J. Invest. Dermatol. 97, 349353.
  • 68
    Hunter, T. (1995) Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80, 225236.
  • 69
    Halaban, R. (1991) Growth factors and tyrosine protein kinases in normal and malignant melanocytes. Cancer Metastasis Rev. 10, 129140.
  • 70
    Loganzo, F., Jr., J. S. Dosik, Y. Zhao, M. J. Vidal, D. M. Nanus, M. Sudol and A. P. Albino (1993) Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene 8, 26372644.
  • 71
    Easty, D. J., S. E. Ganz, C. J. Farr, C. Lai, M. Heryln and D. C. Bennett (1993) Novel and known protein tyrosine kinases and their abnormal expression in human melanoma. J. Invest. Dermatol. 101, 679684.
  • 72
    Shih, I. M. and M. Herlyn (1993) Role of growth factors and their receptors in the development and progression of melanoma. J. Invest. Dermatol. 100, 196S203S.
  • 73
    Folkman, J. (1992) The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3, 6571.
  • 74
    Barnhill, R. L. and M. A. Levy (1993) Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. Am. J. Pathol. 143, 99104.
  • 75
    Mason, I. J. (1994) The ins and outs of fibroblast growth factors. Cell 78, 547552.
  • 76
    Reed, J. A., N. S. McNutt and A. P. Albino (1994) Differential expression of basic fibroblast growth factor (bFGF) in melanocyte lesions demonstrated by in situ hybridization. Implications for tumor progression. Am. J. Pathol. 144, 329336.
  • 77
    Houghton, A. N., D. Mintzer, C. Cordon Cardo, S. Welt, B. Fliegel, S. Vadhan, E. Carswell, M. R. Melamed, H. F. Oettgen and I. J. Old (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 82, 12421246.
  • 78
    Johnson, J. P., B. G. Stade, B. Holzman, W. Schwable and G. Reithmuller (1989) De novo expression of intercellular adhesion molecule-1 in melanoma correlates with increased risk of metastases. Proc. Natl. Acad. Sci. USA 86, 641644.
  • 79
    Soballe, P. W. and M. Herlyn (1994) Cellular pathways leading to melanoma differentiation: therapeutic implications. Melanoma Res. 4, 213223.